Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing CB 2679d/ISU304, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis for development and manufacturing of the Factor IX products through Phase I/II clinical trials. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CBIO
CUSIP87611R30
Phone650-266-8674
Debt
Debt-to-Equity RatioN/A
Current Ratio57.19
Quick Ratio57.19
Price-To-Earnings
Trailing P/E Ratio-1.39
Forward P/E Ratio-4.12
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.02 million
Price / Sales120.92
Cash FlowN/A
Price / CashN/A
Book Value$5.29 per share
Price / Book1.95
Profitability
EPS (Most Recent Fiscal Year)($7.45)
Net Income$-21,560,000.00
Net Margins-2,983.40%
Return on Equity-27.51%
Return on Assets-25.68%
Miscellaneous
Employees13
Outstanding Shares11,940,000
Market Cap$120.14 million
Catalyst Biosciences (NASDAQ:CBIO) Frequently Asked Questions
What is Catalyst Biosciences' stock symbol?
Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO."
When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work?
Catalyst Biosciences's stock reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split.
How were Catalyst Biosciences' earnings last quarter?
Catalyst Biosciences Inc (NASDAQ:CBIO) issued its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.08. Catalyst Biosciences had a negative return on equity of 27.51% and a negative net margin of 2,983.40%. View Catalyst Biosciences' Earnings History.
When is Catalyst Biosciences' next earnings date?
What price target have analysts set for CBIO?
2 brokers have issued 12-month price objectives for Catalyst Biosciences' stock. Their forecasts range from $12.50 to $35.00. On average, they anticipate Catalyst Biosciences' share price to reach $23.75 in the next year. This suggests a possible upside of 129.9% from the stock's current price. View Analyst Price Targets for Catalyst Biosciences.
What is the consensus analysts' recommendation for Catalyst Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Biosciences.
Who are some of Catalyst Biosciences' key competitors?
Some companies that are related to Catalyst Biosciences include Unum Therapeutics (UMRX), Rigel Pharmaceuticals (RIGL), Depomed (DEPO), Akebia Therapeutics (AKBA), Forty Seven (FTSV), Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Stemline Therapeutics (STML), Aduro BioTech (ADRO), Synergy Pharmaceuticals (SGYP), Magenta Therapeutics (MGTA), Merus (MRUS), ZEALAND PHARMA/S (ZEAL), ZIOPHARM Oncology (ZIOP) and Dermira (DERM).
Who are Catalyst Biosciences' key executives?
Catalyst Biosciences' management team includes the folowing people:
- Dr. Nassim Usman, Pres, CEO & Director (Age 58)
- Mr. Fletcher Payne, Chief Financial Officer (Age 55)
- Dr. Howard Levy, Chief Medical Officer (Age 64)
- Dr. Charles S. Craik, Co-Founder and Chairman of Scientific Advisory Board
- Mr. Andrew Hetherington M.B.A., Sr. VP of Technical Operations
Has Catalyst Biosciences been receiving favorable news coverage?
Headlines about CBIO stock have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Catalyst Biosciences earned a news impact score of 0.08 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.02 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. View Recent Headlines for Catalyst Biosciences.
Who are Catalyst Biosciences' major shareholders?
Catalyst Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Acuta Capital Partners LLC (6.95%), Nexthera Capital LP (6.59%), BlackRock Inc. (6.51%), Point72 Asset Management L.P. (5.03%), Renaissance Technologies LLC (4.91%) and Marshall Wace LLP (4.61%). View Institutional Ownership Trends for Catalyst Biosciences.
Which major investors are selling Catalyst Biosciences stock?
Which major investors are buying Catalyst Biosciences stock?
CBIO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BlackRock Inc., Marshall Wace LLP, Nexthera Capital LP, GSA Capital Partners LLP, Millennium Management LLC, Acadian Asset Management LLC and Point72 Europe London LLP. View Insider Buying and Selling for Catalyst Biosciences.
How do I buy shares of Catalyst Biosciences?
Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Biosciences' stock price today?
One share of CBIO stock can currently be purchased for approximately $10.33.
How big of a company is Catalyst Biosciences?
Catalyst Biosciences has a market capitalization of $120.14 million and generates $1.02 million in revenue each year. The biopharmaceutical company earns $-21,560,000.00 in net income (profit) each year or ($7.45) on an earnings per share basis. Catalyst Biosciences employs 13 workers across the globe.
How can I contact Catalyst Biosciences?
Catalyst Biosciences' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-8674 or via email at [email protected]
MarketBeat Community Rating for Catalyst Biosciences (NASDAQ CBIO)
MarketBeat's community ratings are surveys of what our community members think about Catalyst Biosciences and other stocks. Vote "Outperform" if you believe CBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
